BCAX - Conference and earnings call announcements

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that company leadership will participate in multiple upcoming investor conferences. Ryan Cohlhepp, Pharm.D., President and Chief Operating Officer at Bicara will take part in fireside chats at: TD Cowen 46th Annual Health Care Conference Date and Time: Monday, March 2, 1:10-1:40 p.m. ET in Boston Barclays 28th Annual Global Healthcare Conference Date and Time: Tuesday, March 10, 11:30-11:55 a.m. ET in Miami Bicara management will also attend the 2026 Jeffe

Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 Anticipates multiple expansion cohort data readouts in 2026 to further characterize ficerafusp alfa's profile in HPV-negative HNSCC and support potential expansion into other solid tumor types, including colorectal cancer Claire Mazumdar, PhD, MBA, Chief Executive Officer, to present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12 at 11:15 a.m. PT (2:15 p.m. ET) BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara's website under Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutic

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that management will participate in multiple upcoming investor conferences: Cantor Global Healthcare Conference 2025Date and Time: Wednesday, September 3, 2025 at 10:55 a.m. ET 2025 Wells Fargo Healthcare ConferenceDate and Time: Wednesday, September 3, 2025 at 2:15 p.m. ET Morgan Stanley 23rd Annual Global Healthcare ConferenceDate and Time: Monday, September 8, 2025 at 4:05 p.m. ET Live webcasts of the fireside chats will be accessible through the Investor

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 3:20 p.m. ET. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara's website under Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharma

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET. A live webcast of the presentation will be available at Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional t

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference in New York, NY on Tuesday, November 19, 2024 at 9:10 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Bicara's website at www.bicara.com. An archived replay of the webcast will be available for approximately 90 days following the presentation. About Bicara Therapeutics